Brief: Design Therapeutics Q2 Basic EPS USD -0.34

Design Therapeutics

07/08/2025 21:01

Overview

Design Therapeutics Q2 net loss of $19.1 mln misses analyst expectations

Favorable PK data for DT-216P2 in Friedreich Ataxia; U.S. trials on hold

Outlook

Company plans to address FDA clinical hold with clinical data

Result Drivers

FDA HOLD - U.S. trials for DT-216P2 are on hold due to FDA concerns about starting dose, with plans to address using clinical and nonclinical data

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
Miss
-$19.08 mln
-$18.90 mln (3 Analysts)
Q2 Basic EPS
-$0.34
Q2 Operating Expenses
$21.57 mln
Q2 Operating Income
-$21.57 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Design Therapeutics Inc is $5.00, about 13% above its August 6 closing price of $4.35

Press Release: ID:nGNX17c95l

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)